Antiatherothrombotic effects of nicotinic acid

Atherosclerosis

Volumn 171, Issue 1, 2003, Pages 87-96

  Rosenson, Robert S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Coronary heart disease risk; Fibrinolysis; Lipids; Niacin; Thrombosis; Viscosity

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD FLOW; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM CELL; GLYCOLYSIS; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; RISK FACTOR; THROMBOSIS;

EID: 0344420098     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.07.003     Document Type: Article

References (91)

1. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
2. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84:1987;2995-2998.
3. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 279:1998;1643-1650.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program (Adult Treatment Panel III): full report. NIH Publication No. 02-5215. Bethesda, MD: NIH National Heart, Lung, and Blood Institute; September 2002.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
6. Canner P.L., Berge K.G., Wenger N.K.et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll Cardiol. 8:1986;1245-1255.
7. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
8. Brown G., Albers J.J., Fisher L.D.et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323:1990;1289-1298.
9. Brown B.G., Zhao X.Q., Chait A.et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345:2001;1583-1592.
10. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr. Atheroscler. Rep. 2:2000;36-46.
11. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 99:1999;1959-1964.
12. Superko H.R., Krauss R.M. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 95:1992;69-76.
13. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am. J. Cardiol. 88:2001;270-274.
14. Rosenson R.S., Otvos J.D., Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90:2002;89-94.
15. Chait A., Brazg R.L., Tribble D.L., Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 94:1993;350-356.
16. Hayek T., Oiknine J., Dankner G., Brook J.G., Aviram M. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur. J. Clin. Chem. Clin. Biochem. 33:1995;721-725.
17. Navab M., Hama S.Y., Cooke C.J.et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41:2000;1481-1494.
18. Parthasarathy S., Barnett J., Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1044:1990;275-283.
19. Mehta J.L., Chen L.Y. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J. Lab. Clin. Med. 127:1996;287-295.
20. Austin M.A. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am. J. Cardiol. 83:1999;13F-16F.
21. Cui Y., Blumenthal R.S., Flaws J.A.et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161:2001;1413-1419.
22. Stein J.H., Rosenson R.S. Lipoprotein Lp(a) excess and coronary heart disease. Arch. Intern. Med. 157:1997;1170-1176.
23. Berg K., Dahlén G., Christophersen B., Cook T., Kjekshus J., Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52:1997;254-261.
24. Carlson L.A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J. Intern. Med. 226:1989;271-276.
25. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 17:1997;2020-2028.
26. Sakai T., Kamanna V.S., Kashyap M.L. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 21:2001;1783-1789.
27. Shepherd J., Packard C.J., Patsch J.R., Gotto A.M. Jr., Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest. 63:1979;858-867.
28. Atmeh R.F., Shepherd J., Packard C.J. Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. Biochim Biophys Acta. 751:1983;175-188.
29. Van J.T., Pan J., Wasty T., Chan E., Wu X., Charles M.A. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am. J. Cardiol. 89:2002;1306-1308.
30. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J. Lipid Res. 32:1991;383-394.
31. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240.
32. Blankenhorn D.H., Azen S.P., Crawford D.W.et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 83:1991;438-447.
33. Blankenhorn D.H., Selzer R.H., Crawford D.W.et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 88:1993;20-28.
34. Mack W.J., LaBree L., Liu C., Selzer R.H., Hodis H.N. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis. 150:2000;371-379.
35. Cashin-Hemphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 264:1990;3013-3017.
36. Zhao X.Q., Yuan C., Hatsukami T.S.et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol. 21:2001;1623-1629.
37. Rong J.X., Li J., Reis E.D.et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 104:2001;2447-2452.
38. Khoo J.C., Miller E., McLoughlin P., Steinberg D. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J. Lipid Res. 31:1990;645-652.
39. Ylä-Herttuala S. Oxidized LDL and atherogenesis. Ann. N.Y. Acad. Sci. 874:1999;134-137.
40. Rosenson R.S., Koenig W. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Curr. Opin. Cardiol. 17:2002;325-331.
41. Sampietro T., Bigazzi F., Dal Pino B.et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? Circulation. 105:2002;11-14.
42. Kashyap M.L., McGovern M.E., Berra K.et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation in patients with dyslipidemia. Am. J. Cardiol. 89:2002;672-678.
43. Grundy S.M., Vega G.L., McGovern M.E.et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch. Intern. Med. 162:2002;1568-1576.
44. Chen L.Y., Mehta J.L. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci. 55:1994;1815-1821.
45. Kuvin J.T., Rämet M.E., Patel A.R., Pandian N.G., Mendelsohn M.E., Karas R.H. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J. 144:2002;165-172.
46. Andrews T.C., Whitney E.J., Green G., Kalenian R., Personius B.E. Effect of gemfibrozil ± niacin ± cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am. J. Cardiol. 80:1997;831-835.
47. Rosenson R.S., Lowe G.D.O. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 140:1998;271-280.
48. Hoffman C.J., Lawson W.E., Miller R.H., Hultin M.B. Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb. 14:1994;1737-1740.
49. Silveira A., Karpe F., Blomback M., Steiner G., Walldius G., Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb. 14:1994;60-69.
50. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol. 19:1999;1051-1059.
51. Chesney C.M., Elam M.B., Herd J.A.et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am. Heart J. 140:2000;631-636.
52. Lopez Y., Paloma M.J., Rifon J., Cuesta B., Paramo J.A. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res. 93:1999;71-78.
53. Dearing B.D., Lavie C.J., Lohmann T.P., Genton E. Niacin-induced clotting factor synthesis deficiency with coagulopathy. Arch. Intern. Med. 152:1992;861-863.
54. Kowalska M.A., Tuszynski G.P., Capuzzi D.M. Plasma lipoproteins mediate platelet adhesion. Biochem Biophys Res Commun. 172:1990;113-118.
55. Corash L., Andersen J., Poindexter B.J., Schaefer E.J. Platelet function and survival in patients with severe hypercholesterolemia. Arteriosclerosis. 1:1981;443-448.
56. Carvalho A.C., Colman R.W., Lees R.S. Platelet function in hyperlipoproteinemia. N. Engl. J. Med. 290:1974;434-438.
57. Zhao B. Role of lipoproteins in platelet activation. Blood Coagul Fibrinolysis. 7:1996;270-273.
58. Aviram M., Brook J.G. Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis. 13:1983;344-350.
59. Desai K., Bruckdorfer K.R., Hutton R.A., Owen J.S. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J. Lipid Res. 30:1989;831-840.
60. Koller E., Koller F., Binder B.R. Purification and identification of the lipoprotein binding proteins from human blood platelet membrane. J. Biol. Chem. 264:1989;12412-12418.
61. 2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation. 81:1990;1784-1791.
62. Brown S.L., Sobel B.E., Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation. 92:1995;767-772.
63. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 94:1996;2057-2063.
64. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
65. Sironi L., Mussoni L., Prati L.et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol. 16:1996;89-96.
66. Weiner M., DeCrinis K., Redisch W., Steele J.M. Influence of some vasoactive drugs on fibrinolytic activity. Circulation. 19:1959;845-848.
67. Weiner M., Redisch W., Steele J.M. Occurrence of fibrinolytic activity following administration of nicotinic acid. Proc. Soc. Exp. Biol. Med. 98:1958;755-757.
68. Rosenson R.S. Viscosity and ischemic heart disease. J. Vas Med Biol. 4:1993;206-212.
69. Lowe G.D., Lee A.J., Rumley A., Price J.F., Fowkes F.G. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br. J. Haematol. 96:1997;168-173.
70. Yarnell J.W., Baker I.A., Sweetnam P.M.et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation. 83:1991;836-844.
71. Rosenson R.S., Shott S., Lu L., Tangney C.C. Hypertriglyceridemia and other factors associated with plasma viscosity. Am. J. Med. 110:2001;488-492.
72. Stein J.H., Rosenson R.S. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis. 137:1998;401-405.
73. Stamos T.D., Rosenson R.S. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis. 146:1999;161-165.
74. Rosenson R.S., Shott S., Tangney C.C. Hypertriglyceridemia is associated with an elevated blood viscosity. Rosenson: triglycerides and blood viscosity. Atherosclerosis. 161:2002;433-439.
75. Razavian S.M., Atger V., Giral P.et al. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men. Arterioscler Thromb. 14:1994;361-366.
76. Sloop G.D., Garber D.W. The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin. Sci. (London). 92:1997;473-479.
77. Epand R.M., Stafford A., Leon B.et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb. 14:1994;1775-1783.
78. Neufeld M., Nofer J.R., Becker P., Langer C., Assmann G., Junker R. High-density lipoproteins inhibit fibrinogen binding on adenosine diphosphate-activated monocytes. Blood Coagul Fibrinolysis. 11:2000;505-509.
79. Montefusco S., Iannaci G., Gnasso A., Cortese C., Lamenza F., Postiglione A. Blood and plasma viscosity after acipimox treatment in hypertriglyceridemic patients. Int. J. Clin. Pharmacol Ther Toxicol. 26:1988;492-494.
80. Hamazaki T., Hasunuma K., Kobayashi S., Shishido H., Yano S. The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid. Atherosclerosis. 55:1985;107-113.
81. Philipp C.S., Cisar L.A., Saidi P., Kostis J.B. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. Am. J. Cardiol. 82:1998;697-699.
82. Giles W.H., Croft J.B., Greenlund K.J., Ford E.S., Kittner S.J. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey. Am. Heart J. 139:2000;446-453.
83. Bostom A.G., Rosenberg I.H., Silbershatz H.et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann. Intern. Med. 131:1999;352-355.
84. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
85. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Schouten E.G. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 288:2002;2023-2031.
86. Schnyder G., Roffi M., Pin R.et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N. Engl. J. Med. 345:2001;1593-1600.
87. Schnyder G., Roffi M., Flammer Y., Pin R., Hess O.M. Effect of homocysteinelowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 288:2002;973-979.
88. Garg R., Malinow M., Pettinger M., Upson B., Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. Am. Heart J. 138:1999;1082-1087.
89. Lamping K.A., Menahan L.A., Gross G.J. Nicotinic acid, free fatty acids and myocardial function during coronary occlusion and reperfusion in the dog. J. Pharmacol. Exp. Ther. 231:1984;532-538.
90. Datta S., Das D.K., Engelman R.M.et al. Enhanced myocardial preservation by nicotinic acid, an antilipolytic compound: mechanism of action. Basic Res. Cardiol. 84:1989;63-76.
91. Trueblood N.A., Ramasamy R., Wang L.F., Schaefer S. Niacin protects the isolated heart from ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 279:2000;H764-H771.